Login to Your Account

Other News To Note

Tuesday, August 14, 2012
• NPS Pharmaceuticals Inc., of Bedminster, N.J., said that the Prescription Drug User Fee Act action date for its NDA for Gattex (teduglutide) for the treatment of adult patients with short bowel syndrome has been extended by three months to Dec. 30.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription